Invesaro

Stocks Comparison

Avantor vs 10x Genomics: revenue, profit, margins and growth compared

Avantor brought in $6.6B of revenue in fiscal 2025, 10x Genomics $642.8M in fiscal 2025. Revenue changed by -3.4% at Avantor and +5.2% at 10x Genomics on the year before, so 10x Genomics grew faster. Avantor kept -8.1% of its revenue as net profit, 10x Genomics -6.8%. Free cash flow was $495M at Avantor and $130.1M at 10x Genomics.

Side by side, latest fiscal year

AVTRTXG
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$6.6B$642.8M
Revenue growth-3.4%+5.2%
Net income-$530.2M-$43.5M
Net margin-8.1%-6.8%
Free cash flow$495M$130.1M
Free cash flow margin7.6%20.2%
Earnings per share (diluted)-$0.78-$0.35
Cash$365.4M$474M
Debt$3.9Bn/a
Price to earningsn/an/a
Market value$10.3B$11.2B
Dividend yieldn/an/a
Rank by revenue in sector#101 of 451 · Industrials#299 of 451 · Industrials

Over the years

Revenue
AVTR FY2019: $5.9BAVTR FY2019: $6BAVTR FY2020: $6.4BAVTR FY2020: $7.4BAVTR FY2022: $7.5BAVTR FY2023: $7BAVTR FY2024: $6.8BAVTR FY2025: $6.6BTXG FY2019: $146.3MTXG FY2019: $245.9MTXG FY2020: $298.8MTXG FY2021: $490.5MTXG FY2022: $516.4MTXG FY2023: $618.7MTXG FY2024: $610.8MTXG FY2025: $642.8MFY19FY20FY21FY22FY23FY24FY25
AVTR $6.6BTXG $642.8M
Net income
AVTR FY2019: -$86.9MAVTR FY2019: $37.8MAVTR FY2020: $116.6MAVTR FY2020: $572.6MAVTR FY2022: $686.5MAVTR FY2023: $321.1MAVTR FY2024: $711.5MAVTR FY2025: -$530.2MTXG FY2019: -$112.5MTXG FY2019: -$31.3MTXG FY2020: -$542.7MTXG FY2021: -$58.2MTXG FY2022: -$166MTXG FY2023: -$255.1MTXG FY2024: -$182.6MTXG FY2025: -$43.5MFY19FY20FY21FY22FY23FY24FY25
AVTR -$530.2MTXG -$43.5M
Net margin
AVTR FY2019: -1.5%AVTR FY2019: 0.6%AVTR FY2020: 1.8%AVTR FY2020: 7.8%AVTR FY2022: 9.1%AVTR FY2023: 4.6%AVTR FY2024: 10.5%AVTR FY2025: -8.1%TXG FY2019: -76.9%TXG FY2019: -12.7%TXG FY2020: -181.6%TXG FY2021: -11.9%TXG FY2022: -32.1%TXG FY2023: -41.2%TXG FY2024: -29.9%TXG FY2025: -6.8%FY19FY20FY21FY22FY23FY24FY25
AVTR -8.1%TXG -6.8%
Revenue growth
AVTR FY2019: +3.0%AVTR FY2020: +5.8%AVTR FY2020: +15.5%AVTR FY2022: +1.7%AVTR FY2023: -7.3%AVTR FY2024: -2.6%AVTR FY2025: -3.4%TXG FY2019: +68.1%TXG FY2020: +21.5%TXG FY2021: +64.1%TXG FY2022: +5.3%TXG FY2023: +19.8%TXG FY2024: -1.3%TXG FY2025: +5.2%FY19FY20FY21FY22FY23FY24FY25
AVTR -3.4%TXG +5.2%
Free cash flow
AVTR FY2019: $162.8MAVTR FY2019: $302.4MAVTR FY2020: $868.2MAVTR FY2020: $842.5MAVTR FY2022: $710.2MAVTR FY2023: $723.6MAVTR FY2024: $692MAVTR FY2025: $495MTXG FY2019: -$82.7MTXG FY2019: -$8.1MTXG FY2020: -$254.6MTXG FY2021: -$122.7MTXG FY2022: -$165.3MTXG FY2023: -$63.8MTXG FY2024: -$5.7MTXG FY2025: $130.1MFY19FY20FY21FY22FY23FY24FY25
AVTR $495MTXG $130.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about Avantor and 10x Genomics

Which is bigger by revenue, Avantor or 10x Genomics?

Avantor is bigger by revenue: $6.6B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.

Which keeps more of its revenue as profit, Avantor or 10x Genomics?

Avantor had a net margin of -8.1% in fiscal 2025; 10x Genomics had -6.8% in fiscal 2025.

Which grew revenue faster, Avantor or 10x Genomics?

In their latest fiscal years revenue changed by -3.4% at Avantor and +5.2% at 10x Genomics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies